Cancer Research UK and the Cancer Research Technology Pioneer Fund are committing £2.5 million in collaboration with the US’ National Cancer Institute to tackle RAS, one of the most common driving mutations in aggressive, hard to treat cancers.
Four research powerhouses have come together to launch an international project aiming to set up a large, globally accessible, bank of new cancer cell culture models for the research.